{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AB-101", "query": { "intervention": "AB-101" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T23:37:25.452Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03592121", "title": "Study to Investigate the Effect of AB-101 in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sexual Dysfunction", "Sexual Arousal Disorder", "Sexual Dysfunction, Physiological", "Breast Cancer", "Nipple Disorder", "Neuropathy", "Cancer of Breast" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Applied Biology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 3, "start_date": "2018-07-09", "completion_date": "2019-10-12", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-09-05T23:37:25.452Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03592121" }, { "nct_id": "NCT06265220", "title": "AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis - WHO Class III", "Lupus Nephritis - WHO Class IV", "Refractory Systemic Lupus Erythematosus", "SLE" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2024-04-03", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-09-05T23:37:25.452Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265220" }, { "nct_id": "NCT05883449", "title": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Hodgkin Lymphoma", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "AFM13", "type": "DRUG" }, { "name": "AB-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affimed GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-10-10", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-09-05T23:37:25.452Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05883449" }, { "nct_id": "NCT06581562", "title": "Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis", "Pemphigus Vulgaris", "Granulomatosis With Polyangiitis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IRIS Research and Development, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-05-15", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-05T23:37:25.452Z", "location_count": 1, "location_summary": "Plantation, Florida", "locations": [ { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581562" }, { "nct_id": "NCT04673617", "title": "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-03-29", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-09-05T23:37:25.452Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673617" } ] }